GDF15 and lung carcinoma: In the analysis of patients with early-stage lung cancer, the four-biomarker panel including MIC-1 identified a sensitivity of 83.9% at a specificity of 95%; notably, the sensitivity for early stage lung cancer by the four-biomarker panel would increase up to 92.9% (95% CI, 87.7% to 96.4%) when the specificity was decreased to 90%, at a cut-off probability value of 0.267.